---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-294309"
form_type: "8-K"
ticker: "SANA"
cik: "0001770121"
company_name: "Sana Biotechnology, Inc."
filed_at: "2022-11-29T23:59:59+00:00"
generated_at: "2026-06-21T12:22:31.176900+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Sana Biotech prioritizes pipeline, cuts 15% staff, halts SC187; maintains cash runway into 2025

## Summary
- Headcount reduced by ~15%; expects ~$7.9M in cash severance and ~$2.2M non-cash stock-based comp charges.
- Discontinues internal investment in SC187 (cardiomyocytes for heart failure) to focus on core programs.
- SC291 (CD19 CAR T) IND on track for 2022; initial clinical data expected in 2023.
- SC263 and SG295 INDs expected in 2023; SC451 and SC255 INDs in 2024.
- Cash runway extended into 2025; program timelines for lead programs not impacted.

## SEC filing metadata
- accession: 0001193125-22-294309
- form_type: 8-K
- ticker: SANA
- cik: 0001770121
- company_name: Sana Biotechnology, Inc.
- filed_at: 2022-11-29T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770121/000119312522294309/0001193125-22-294309-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770121/000119312522294309/d191955d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-294309
- JSON: https://secwatch.observer/filing/0001193125-22-294309.json
- Plain text: https://secwatch.observer/filing/0001193125-22-294309.txt

## Key facts
- Restructurings & Charges
  Sana Biotechnology, Inc. announced a restructuring with charges of approximately $7.9 million of cash-based expenses related to employee severance, benefits and related costs; and approximately $2.2 million non-cash stock-based (approximately 15%).
  - Type: restructuring
  - Charge: approximately $7.9 million of cash-based expenses related to employee severance, benefits and related costs; and approximately $2.2 million non-cash stock-based
  - Headcount: approximately 15%
  source text: On November 29, 2022, Sana Biotechnology, Inc. (“Sana”) issued a press release announcing a portfolio prioritization and corporate restructuring designed to optimize development of its programs at or nearing clinical development, to continue investments in its core research platforms and innovation, and to maintain a strong balance sheet with an expected cash runway into 2025. As part of the prioritization and restructuring, Sana will reduce its workforce by approximately 15% by the end of 2022. In connection with the restructuring, Sana anticipates it will incur approximately $7.9 million of cash-based expenses related to employee severance, benefits and related costs, primarily in the fourth quarter of 2022, when it anticipates that the restructuring will be substantially complete. In addition, Sana expects to record a non-cash stock-based compensation charge of approximately $2.2 million related to modification of equity awards for employees impacted by the restructuring.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1770121/000119312522294309/0001193125-22-294309-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.